Vianney Tricou, Delia Yu, Humberto Reynales, Shibadas Biswal, Xavier Saez-Llorens, Chukiat Sirivichayakul, Pio Lopez, Charissa Borja-Tabora, Lulu Bravo, Pope Kosalaraksa, Luis Martinez Vargas, Maria Theresa Alera, Luis Rivera, Veerachai Watanaveeradej, Reynaldo Dietze, LakKumar Fernando, V Pujitha Wickramasinghe, Edson Duarte Moreira, Asvini D Fernando, Dulanie Gunasekera, Kleber Luz, Ana Lucia Oliveira, Suely Tuboi, Ian Escudero, Yanee Hutagalung, Eric Lloyd, Martina Rauscher, Olaf Zent, Nicolas Folschweiller, Inge LeFevre, Felix Espinoza, Derek Wallace
BACKGROUND: About half of the world's population lives in dengue-endemic areas. We aimed to evaluate the long-term efficacy and safety of two doses of the tetravalent dengue vaccine TAK-003 in preventing symptomatic dengue disease of any severity and due to any dengue virus (DENV) serotypes in children and adolescents. METHODS: In this ongoing double-blind, randomised, placebo-controlled trial, we enrolled healthy participants aged 4-16 years at 26 medical and research centres across eight dengue-endemic countries (Brazil, Colombia, Dominican Republic, Nicaragua, Panama, Philippines, Sri Lanka, and Thailand)...
February 2024: Lancet Global Health